The article presents the development trends of nuclear medicine in oncology. It has been shown that the main trends in modern radiopharmaceutics are closely related to theranostics, i.e., the use of radiopharmaceuticals obtained on the basis of a single delivery vector labeled with diagnostic and therapeutic radionuclides. In nuclear medicine, this approach has found application for the individualization and planning of radionuclide therapy. The results of our own research aimed at the development of radiopharmaceuticals for the diagnosis and radionuclide therapy of cancer are presented.
No takes yet. Share an insight, caveat, or question.
В. И. Чернов (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: